CD80 and interstitial lung disease: The Janus kinase-signal transducer and activator of transcription pathway inhibition in RA-ILD patients resulted in improved pulmonary functions and reduced proinflammatory cytokines like IL-6.80 Moreover, combination therapies of JAK inhibition and T cell inhibition using abatacept, a drug inhibiting CD80/86 and thereby T cell activation, showed slower ILD progression in patients with RA-ILD.81 Although these findings suggest that JAK inhibition might be efficacious to treat fibrosis-related ILD, large-scale randomized controlled trials are needed to confirm this.